Chester G. (``C.G.) Moore, PH.D.



C.G. Moore, Ph.D. is a registered patent attorney and a member of our firm’s Intellectual Property Practice. Dr. Moore concentrates his practice in the fields of biotechnology and chemistry, with a particular emphasis on molecular and cellular biology, small molecule chemistry, medical devices, agricultural chemistry, and food additives.

In addition to the preparation and prosecution of patent applications, C.G. also has broad experience with ex parte reexamination and inter partes review proceedings, appeals to the Patent Trial and Appeal Board (PTAB), managing patent portfolios, drafting patent licenses and opinions, performing due diligence in connection with public financings and acquisitions, and support of litigation involving patents and trademarks.

C.G. gained significant research experience in the life sciences through his work as a research assistant at the Oregon Health Sciences University and later at the Massachusetts General Hospital. He also acquired first-hand experience with the biotechnology industry while working with the New England Organ Bank and the Transplant Resource Center of Maryland.

As a Ph.D. candidate at the Johns Hopkins University School of Medicine, his doctoral research focused on the regulation of glutamate receptors and their interaction with Homer proteins, demonstrating a role for coordinated phosphorylation and isomerization.


  • “Bioscience Firms Integral to Economy,” The Frederick News-Post • (April 28, 2014).
  • “A prolyl-isomerase mediates dopamine-dependent plasticity and cocaine motor sensitization,” 154 Cell 637 (Co-Author) (January 01, 2013).
  • “Preso1 dynamically regulates group I metabotropic glutamate receptors,” 15 Nature Neuroscience 836 (Co-Author) (January 01, 2012).
  • “Generic Biologic Drugs: What’s in a Name?,” 5 The SciTech Lawyer 16 (September 01, 2008).
  • “Federal Circuit: No § 271(e)(1) Safe Harbor for Patented Inventions Not Regulated by FDA,” 6 Health Lawyers Weekly 3 (August 22, 2008).
  • “Killing the Bayh-Dole Act’s Golden Goose,” 8 Tul. J. Tech. & Intell. Prop. 151 (January 01, 2006).
  • “Recent Developments in Intellectual Property Law,” 52 LA. B.J. 294 (January 01, 2004).

Professional Involvement

American Intellectual Property Law Association

Licensing Executives Society

Representative Technologies

Biotechnology / Chemical / Pharmaceutical: small molecule and protein pharmaceutical compounds; DNA regulatory elements; liposomes; antisense DNA vaccines; plasmid expression vectors; insecticides; herbicides; synthetic polymers; genetically-modified organisms; and enzymes.

Medical / Mechanical: suture anchor assemblies; thermal cyclers; vascular stents; remote endarterectomy devices; stent placement and manipulation devices; medication therapy management and quality assurance methods.


  • Tulane University, J.D. 2006.
  • Johns Hopkins University School of Medicine, Ph.D.
    (Neuroscience) 2004.
  • Portland State University, B.S. Biology 1995.
  • Reed College, B.A. Chemistry 1990.

Bar Admissions

  • Maryland, 2015
  • District of Columbia, 2013
  • Louisiana, 2006 (currently inactive)
  • United States Patent and Trademark Office, 2003

Court Admissions

  • U.S. Court of Appeals for the Federal Circuit
  • U.S. Court of Appeals for the Fifth Circuit
  • U.S. District Court for the Eastern District of LA
  • U.S. District Court for the Middle District of LA
  • U.S. District Court for the Northern District of LA
MMV IP Footer

10 S. Market St., 2nd Floor
Frederick, MD 21701


7900 Westpark Dr., Suite A100
McLean, VA 22102

Contact Us